Simon Kloock, Niklas Haerting, Gloria Herzog, Marie Oertel, Niklas Geiger, Andreas Geier, Vasco Sequeira, Alexander Nickel, Michael Kohlhaas, Martin Fassnacht, Ulrich Dischinger
(1) Background: Modulators of the Neuropeptide Y (NPY) system are involved in energy metabolism, but the effect of NPY receptor antagonists on metabolic-dysfunction-associated steatotic liver disease (MASLD), a common obesity-related comorbidity, are largely unknown. In this study, we report on the effects of antagonists of the NPY-2 receptor (Y2R) in comparison with empagliflozin and semaglutide, substances that are known to be beneficial in MASLD. (2) Methods: Diet-induced obese (DIO) male Wistar rats were randomized into the following treatment groups: empagliflozin, semaglutide ± PYY3-36 , the Y2R antagonists JNJ 31020028 and a food-restricted group, as well as a control group...
March 21, 2024: Nutrients